MarketCap
Facebook
X
TelegramQuarterly report 2023-Q1
added 05-15-2023
Lannett Company Total Current Liabilities 2011-2026 | LCI
Annual Total Current Liabilities Lannett Company
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 105 M | 90.5 M | 215 M | 177 M | 201 M | 192 M | 307 M | 44.1 M | 47 M | 33.1 M | 40.4 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 307 M | 33.1 M | 132 M |
Total Current Liabilities of other stocks in the Drug manufacturers industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AcelRx Pharmaceuticals
ACRX
|
3.81 M | - | 7.5 % | $ 6.35 M |  USA |
 |
Agile Therapeutics
AGRX
|
20.8 M | - | 10.11 % | $ 58.2 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
11.4 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
125 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
1.03 B | - | - | $ 11.5 B | USA |
 |
Eagle Pharmaceuticals
EGRX
|
111 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
539 M | - | - | $ 28.9 M |  Irlanda |
 |
DURECT Corporation
DRRX
|
27 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
21.9 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
115 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
48.8 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
9.65 M | - | - | $ 36.6 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
31.6 M | $ 3.19 | 2.08 % | $ 44.9 M | USA |
 |
Bausch Health Companies
BHC
|
4.3 B | $ 5.79 | 1.14 % | $ 2.11 B |  Canada |
 |
Tilray
TLRY
|
433 M | $ 7.03 | 4.61 % | $ 4.34 B | Canada |
 |
Harrow Health
HROW
|
96.3 M | $ 38.36 | 3.4 % | $ 1.41 B | USA |
 |
Canopy Growth Corporation
CGC
|
94.4 M | $ 1.11 | 2.48 % | $ 119 M | Canada |
 |
Veru
VERU
|
11.9 M | $ 2.41 | 1.26 % | $ 325 M | USA |
 |
Jupiter Wellness
JUPW
|
5.98 M | - | - | $ 33.6 M | USA |
 |
Viatris
VTRS
|
6.75 B | $ 13.96 | 0.9 % | $ 16.8 B | USA |
 |
Neoleukin Therapeutics
NLTX
|
16.4 M | - | - | $ 193 M | Canada |
 |
Evolus
EOLS
|
75.3 M | $ 4.34 | 0.12 % | $ 280 M | USA |
 |
Emergent BioSolutions
EBS
|
651 M | $ 8.66 | 5.1 % | $ 443 M | USA |
 |
Organogenesis Holdings
ORGO
|
77.5 M | $ 2.49 | 4.41 % | $ 328 M | USA |
 |
Pacira BioSciences
PCRX
|
310 M | $ 24.1 | 0.17 % | $ 1.11 B | USA |
 |
PetIQ
PETQ
|
190 M | - | 1.64 % | $ 400 M | USA |
 |
ProPhase Labs
PRPH
|
16.1 M | - | - | $ 5.07 M | USA |
 |
Relmada Therapeutics
RLMD
|
6.43 M | $ 7.56 | 2.44 % | $ 298 M | USA |
 |
Assertio Holdings
ASRT
|
128 M | $ 18.05 | 0.17 % | $ 116 M | USA |
 |
Radius Health
RDUS
|
94.8 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
50 M | - | -4.76 % | $ 65.3 M | USA |
 |
cbdMD
YCBD
|
8.62 M | $ 0.74 | -0.99 % | $ 3.19 M | USA |
 |
OptiNose
OPTN
|
177 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
5.73 M | $ 1.06 | 4.46 % | $ 52.9 M | USA |
 |
PLx Pharma
PLXP
|
11.9 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
33.5 M | $ 8.77 | 4.53 % | $ 767 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
4.1 M | $ 2.44 | 3.62 % | $ 3.03 M | USA |
 |
Zomedica Corp.
ZOM
|
9.45 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
9.17 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
9.58 M | $ 0.94 | -0.1 % | $ 33.8 M | USA |
 |
Tricida
TCDA
|
29.5 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
7.4 M | $ 0.63 | -3.05 % | $ 2.7 M |  China |
 |
TherapeuticsMD
TXMD
|
4.78 M | $ 2.08 | 1.4 % | $ 24.1 M | USA |